Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Leukaemia; Lymphoma; Lymphoproliferative disorders
- Focus Therapeutic Use
- 16 Oct 2018 Planned End Date changed from 1 Jan 2015 to 1 Dec 2020.
- 16 Oct 2018 Status has been changed to active, no longer recruiting.
- 07 Jun 2016 Results of two completed phase II trials (NCT00436618 and NCT00918333) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology